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Summary 
Insulin-dependent  diabetes meUitus (IDDM) in NOD/Lt mice represents a complex polygenic 
disease. NOR/Lt is a recombinant congenic strain (RCS) in which limited regions of the NOD/Lt 
genome have been replaced by genome from the C57BL/KsJ strain.  NOR. mice are insulitis 
resistant and diabetes free despite genetic identity with NOD at numerous chromosomal regions 
containing previously described insulin-dependent  diabetes (Idd) genes, including the strongly 
diabetogenic  H2g 7 major histocompatibility  complex (MHC)  haplotype.  The present  study 
revealed BKs-derived genome on segments of chromosomes (Chr) 1, 2, 4, 5, 7, 11, 12, and 18, 
approximating 11.6% of the total NOR genome analyzed.  (NOD  x  NOR)F2 segregation 
analysis was employed to identify chromosomal regions in NOR containing Idd resistance alleles. 
IDDM developed in 33%  (10/30)  of F1 females, and 29.3%  (36/123)  of F2 females aged to 1 
yr. A previously unrecognized diabetes resistance locus (designated Idcl13") strongly protective 
in homozygous state was identified on NOR Chr 2 in linkage with the Illcr structural gene. 
The existence of this locus was confirmed by construction of a NOD stock congenic for NOR- 
derived markers on Chr 2. Our analysis shows the utility of RCS and congenic stocks for the 
identification  and isolation  of non-MHC genes with strong antidiabetogenic  functions. 
N 
'OR/Lt is an insulitis-resistant and diabetes-free recom- 
binant congenic strain (RCS) produced from an iso- 
lated genetic contamination within a NOD/Lt pedigree line 
by the C57BL/KsJ  (BKs) strain  (1). Preliminary genetic 
screening of NOR/Lt for linkage markers delineating NOD- 
derived insulin-dependent  diabetes (Idd),  genes showed that 
both strains shared the diabetogenic H2~ 7 MHC haplotype 
(Iddl, chromosome [Chr 17]) as well as NOD genome on 
regions of Chr 9, 3, 6,  7, and 14 previously shown to en- 
compass Idd2, 3 and 10, 6, 7, and 8, respectively (1, 2). The 
BKs strain, first identified as a MHC-incompatible substrain 
of C57BL/6J (B6), itself appears to be a RCS resulting from 
a genetic contamination orB6, most probably by the DBA/2J 
strain (3). Thus, the NOR/Lt stock apparently carried genetic 
input from three distinct inbred strains: NOD/Lt, B6, and 
possibly DBA/2J. The present  study defines the tripartite 
origins of the NOR/Lt genome more completely, and uses 
segregation analysis to identify a new Idd linkage. Previous 
analyses of Idd genes utilized first backcross (BC1) progeny 
produced by breeding of diabetes-free F1  hybrids  to  the 
NOD parental  strain (4).  Although allowing  detection of 
recessive  NOD susceptibility modifiers, BC1 is less well-suited 
for identification  of strongly penetrant dominant suscepti- 
bility aUdes. Given that the NOD and NOR parental strains 
share significant levels of genetic susceptibility  to insulin- 
dependent diabetes mellitus (IDDM), an F2 generation was 
analyzed since  the effects of NOR-derived Idd resistance 
modifiers could be evaluated in both the homozygous and 
heterozygous states. 
Materials and Methods 
Mice.  NOD/Lt mice have been maintained in our research 
colony by brother-sister mating. Currently, diabetes develops in 
90% of female and 63% of male NOD/Lt mice by 1 yr of age. 
A single NOR/Lt male from the 12th generation of inbreeding 
was used as the progenitor for the (NOD  x  NOR)F1 and F2 
segregants used in this study. All mice were maintained under 
specific pathogen-free  conditions and allowed free access to food 
(diet 96W; Emory  Morse  Co., Guilford,  CT) and acidified  drinking 
water. The NOR/Lt strain is now inbred beyond  the 20th genera- 
tion of  inbreeding  and is available  from  The Animal  Resources  Unit 
of The Jackson Laboratory as a control strain of NOD/Lt. 
Assessment of Diabetes and Insulitis Development.  Female  F1 and 
F2 progeny were monitored for the development of glycosuria 
with Tes-Tape"  (kindly  supplied  by Eli Lilly, Indianapolis, IN). Mice 
were confirmed as diabetic when glycosuria  was 3 + and plasma 
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or upon reaching 1 yr of age, the segregants were necropsied and 
genomic DNA prepared from liver and kidney as previously de- 
scribed (5) for the genotypic analyses  described below. Pancreases 
from 1-yr-old segregants remaining normoglycemic were fixed in 
Bouin's solution and sectioned at three nonoverlapping levels. Sec- 
tions were stained with aldehyde  fuchsin followed  by hematoxylin 
and eosin counterstain to assess residual B cell mass and extent of 
leukocytic infiltration (insulitis). An insulitis index score for each 
mouse pancreas was obtained  as previously  described (6), with scores 
ranging between 0 (no lesions) and 4 (complete islet destruction). 
Genotypic Analysis of NOR/Lt Mice and (NOD  x  NOR)Fz 
Segregants.  Initial genotyping of 53 markers in NOR mice at the 
Fs and F9 generation revealed  recombinant regions of BIG genome 
on Chr 2, 4, 11 and 12 (1). At the 15th generation of inbreeding, 
the NOR strain was further genotyped at an additional 131 markers 
distinguishing NOD from BIG mice, either by our previously  de- 
scribed Southern blot techniques (7, 8) to detect restriction frag- 
ment length variants (RFLV), or by PCR, using oligonucleotide 
primers for mapped simple sequence repeats known to distinguish 
the NOD genome from either B6 or DBA/2J genomes (9, 10). 
After an initial melting of  genomic DNA for 3 min at 94~  PCR 
products were generated over 30 cycles on a PTC-100 Thermal Cy- 
cler (MJ Research, Watertown, MA). Each cycle  was programmed 
for a denaturation step at 94~  for 60 s, followed by primer an- 
nealing at 55~  for 90 s, and extension at 72~  for 120 s. Gener- 
ally, PCP, products were electrophoretically resolved in 4-6% 
Nusieve 3:1 agarose gels (FMC Corp., Rockland, ME), and then 
visualized by ethidium bromide staining. In cases where a locus- 
specific microsatellite  sequence  distinguishing NOD from BIG mice 
varied by <5 bp, cx[32P]dCTP-labeled PCR products were gener- 
ated as previously  described (9), electrophoretically  separated in an 
8% acrylamide gel, and then visualized by autoradiography. 
BKs-derived genetic markers were analyzed in all F2 segregants 
to establish which cosegregated with IDDM resistance. Linkage 
of  a BIG-derived  marker with IDDM resistance  was assumed  when 
a statistically significant segregation distortion favoring homozy- 
gosity for the NOD-derived  allele in diabetic F2 progeny was 
balanced by a concurrent skewing towards homozygosity for the 
BiG-derived allele in nondiabetic segregants. Segregation distor- 
tion for a given locus was statistically assessed  by six-term contin- 
geney Chi-square (X  2) analysis. In contingency X  2 analysis, the ex- 
pected number  of the  three possible F2 genotypes within the 
diabetic and nondiabetic populations is based on the actual propor- 
tions of these genotypes in the total population, rather than on 
the theoretical 1:2:1 Mendelian  ratio. Only markers showing a con- 
tingency X  ~ values/>6.5 are listed. 
Results and Discussion 
Expanded  Genotypic Analysis  of NOR/Lt  Mice.  Of 184 
nonrandomly sdected polymorphic loci, 43 were BKs-derived 
(Fig. 1). In addition to previously reported recombinant regions 
on Chr 2, 4, 11, and 12, segments of BKs-derived genome 
on Chr 1, 5, 7, and 18 were found. BKs genome was present 
on proximal and medial Chr 1 (two discrete  segments "~8 
and 12.5 cM in size), distal Chr 2 ('~32-cM segment), distal 
Chr 4 ("~22-cM segment), proximal Chr 5 (~7-cM segment), 
distal Chr 7 (~16.5-cM segment), proximal and medial Chr 
11 (three discrete segments ,,04.5, 24, and 7.5 cM), and prox- 
imal and distal Chr 18 (~13 and 5 cM). A RCS should con- 
tain 12.5% of donor strain genome (11). Since the minimum 
estimated BKs genomic component in NOR totals 167.5 cM, 
and the mouse genome can be estimated as 1,450 cM, the 
BKs component of NOR is estimated at 11.6%,  very close 
to the theoretical 12.5%  for a RCS. Genotyping informa- 
tion provided by Dr. Jiirgen Naggert (The Jackson Labora- 
tory) allowed us to further delineate the BKs genomic con- 
tribution to NOR/Lt as being of  B6 (29/183 loci) or DBA/2 
origin (14/183  loci).  As shown in Fig. 1, Chr 4 and 11 ex- 
hibit a complex mosaic of NOD, B6, and DBA/2-1ike ge- 
homes, whereas only B6 alleles were observed  on the other 
recombinant chromosomes. As mentioned above, NOR con- 
rains nonrecombinant regions of NOD genome on five chro- 
mosomes where Idd susceptibility genes have been previously 
identified (2,  4,  5).  These include Chr 17 (Iddl  =  H2F), 
Chr 9 (Idd2), Chr 3 (both Idd3 and IddlO), Chr 7 (Idd7), and 
Chr  14 (IddS). 
Diabetes and Insulitis in NOR/Lt  vs. (NOD  x  NOR)FI 
and F2 Mice.  Although distinguished from NOD/Lt mice 
in terms of IDDM resistance,  aging NOR/Lt mice devel- 
oped the heavy perivascular  and periductular pancreatic leu- 
kocytic aggregates characteristic of NOD/Lt mice. Whereas 
these.perivascular/periductular  infiltrates in NOR were some- 
times contiguous with one pole of an islet (peri-insulitis), 
islets exhibiting more severe insulitic stages were rare. Insu- 
litis usually not more severe than grade 2 was observed  in 
"~5% of the islets examined in 7-mo-old mice of either sex. 
Outcross of NOD to NOR markedly altered this resistance 
in F1 female progeny. Of 30 FI females monitored for dia- 
betes development through 1 yr of age, 10 (33%) developed 
IDDM. Widespread severe insulitis (index >--3) characteristic 
of NOD parental mice was observed in 17 of the nondiabetic 
females, with only three exhibiting the insulitis resistance 
phenotype characteristic of the NOR parental females. This 
contrasts markedly with the complete absence of IDDM in 
(NOD  x  BKs)F1 females which are heterozygous at all loci, 
including 1-1-2 (5). Of 123 (NOD  x  NOR)F2 females pro- 
duced, 36 (29.3%) became diabetic by 1 yr of age. As ob- 
served in nondiabetic F1 progeny, all stages of insulitis were 
observed in the majority of pancreases of the nondiabetic F2 
segregants.  Only 17/87 (20%) of these latter pancreases ex- 
hibited the insulitis-resistance profile characteristic of the NOR 
parental strain. The proportion of F2 diabetics  (29%),  to- 
gether with a comparable proportion ofinsulitis-resistant  non- 
diabetic segregants (20%)  might suggest segregation of a 
single, weakly dominant NOR-derived insulitis/diabetes re- 
sistance  allele.  However,  the  fact  that  33%  of female  F1 
progeny developed diabetes,  and 90% exhibited more wide- 
spread insulitis than NOR females, indicated a more com- 
plex genetic control. 
Identification of  a New Diabetes Locus on Chr 2.  Genotypic 
analysis of all  123  F2 progeny was performed to establish 
whether Idd resistance alleles were present on any of the eight 
recombinant chromosomes identified in NOR.  NOD and 
NOR progenitors were homozygous for all alleles typed. 
Highly significant linkage with IDDM resistance  was as- 
sociated with homozygosity for NOR alleles on Chr 2. As 
shown in Table 1, the presence of an ldd resistance gene (provi- 
sionally designated Idd13) was established  in an '~4-cM seg- 
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generation of inbreeding.  Markers of BKs origin are boxed, 
with loci originally  derived from DBA/2J in shaded areas, 
and those of C57BL/6J origin in unshaded areas. All markers 
were typed by PCR analysis of locus-spedfic microsatellite 
sequences, except for the following loci. The IFN regulatory 
factor I gene (I1fl) was typed as a Southern blot RFLV with 
the previously described IILF-1 probe (24). The Nos2 locus 
was typed by Southern blot analysis as a BglI KFLV with 
the previously described rat iNOS cDNA (20). Xrav65 was 
typed as previously described (25) by Southern  blot analysis 
as a HindllI RFLV with the JS-6, JS-10 oligonucleotide probes. 
The Pcna locus  was typed as previously described (26) by 
Hinfl/TaqI digestion  of an intron 4 sequence amplified by 
PCK. Similarly, B2m was genotyped by Bgll digestion of a 
PCK product spanning portions of exons 2 and 3 generated 
with  the  oligunucleotide  primers  5'-CACGCCACCCAC- 
CGGAGAATG-3' and 5'-GATGCTGATCACATGTCTCG-3' 
(27). 
Table  1.  Identification of Linkage Markers for BKs-derived Alleles  Contn'buting to  Diabetes Resistance in NOR/Lt  Mice  by 
Segregation Analysis  of Female (NOD  x  NOR)F2 Progeny 
Diabetic  Control 
genotypes  genotypes 
Chr  Marker  NOD:F,:NOK  NOD:F,:NOK  X2(p)" 
1  (37)  D1Mit46  9:24:3  19:41:27  7.4  (<0.0125) 
(42)  DIMit8  11:21:4  18:40:29  6.5  (<0.05) 
2  (54)  B2m  18:17:1  17:41:29  18.2  (<0.0001) 
(56)  111  19:16:1  16:42:29  20.5  (<0.0001) 
(58)  Pcna  18:17:1  16:41:30  19.3  (<0.0001) 
(69)  D2Mit47  16:18:2  18:38:30  13.5  (<0,001) 
(73)  D2Mit48  15:19:2  18:38:28  11.7  (<0.0025) 
4  (53)  D4Mit11  13:18:5  14:45:27  8.5  (<0.0125) 
(66)  Nppa  14:16:6  15:45:26  7.2  (0.025) 
" Markers within all recombinant  regions depicted in Fig.  1 were typed in the F2 segregants,  and 
by Contingency X  2 analysis. Only those  markers  showing X  2 values ~6.5  are listed. 
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significant distortions  in allele frequencies assessed merit of NOR Chr 2 spanning BKs-derived linkage markers 
at/32-microglobulin,  (B2m),//1,  and proliferating  cell nu- 
clear antigen (Pcna). In the F2 diabetic subpopulation,  mice 
homozygous for the NOR allele at any of these three loci 
were rare, whereas they were present at higher than expected 
frequencies in the nondiabetic F2 segregants. Since F2 segre- 
gants either homozygous or heterozygous for the NOD al- 
leles at these loci were equally IDDM susceptible, the sus- 
ceptibility  allele (Idd13  +) was assumed to be dominant over 
the NOR-derived resistance allele (Idd13'). Homozygosity 
for NOR-derived alleles on the region of Chr 2 delineated 
by the III  linkage marker did not prevent development of 
severe insulitis in females remaining diabetes free to 1 yr of 
age. Only 5/29 of nondiabetic  F2 females homozygous for 
NOR/Lt-derived alleles  in this region had mean insulitis scores 
of g 1.0, characteristic of the NOR/Lt parental strain. Simi- 
larly, of the 17/87 F2 segregants that remained insulitis resis- 
tant through 1 yr of age (insulitis scores of g l.0), 12 of these 
mice  were  either  homozygous or  heterozygous for  the 
NOD/Lt-derived I11 allele. Thus, resistance conferred  by ex- 
pression of the NOR-derived Idd13  r allele is not associated 
with  the  ability  to  prevent  expression  of  the  insulitis 
phenotype. 
The strongest Idd linkage on Chr 2 currently is near the 
//lcr and IlIB structural loci. Since  LPS-stimulated IL-1 secre- 
tion is defective in NOD/Lt peritoneal and bone marrow- 
derived macrophages (10, 11), and treatment of prediabetic 
NOD mice with IL-loe prevents IDDM (12), the IL-lol or 
IL-I~ structural gene is a reasonable "candidate" gene to pro- 
pose for Idd13. However, there is no compelling evidence to 
suggest that IDDM results from primary defects in the coding 
sequences of either IL-1 structural  gene. Our unpublished 
data indicate that the IL-1 secretion defect is manifest post- 
transcriptionally. This might result from failure  of NOD mac- 
rophages to differentiate fully from hematopoietic precursors 
(11). Further, in vivo treatment of NOD/Lt mice with IL-2 
or poly [I:C]  (13) restores normal patterns of macrophage 
IL-1 secretion. Most importantly, defective IL-1 secretion is 
observed in cultured peritoneal macrophages from NOR/Lt 
mice (1), which are characterized by B6-like Ill  structural 
genes. Hence, the IL-1 secretion defect in NOD macrophages 
results from complex interactions between the I11 structural 
genes and trans-active factors encoded by other loci. The re- 
duced ability of NOD T cells to acquire immunoregulatory 
activity in a syngeneic mixed lymphocyte reaction (SMLR) 
is partially a function of the IL-1 secretory defect (10). In 
contrast, T cells from NOR can acquire immunoregulatory 
function in a SMLR (1). However, a preliminary study using 
8-12-wk-old F2 males revealed that this immunodysfunction 
did not segregate with the I11  structural genes. 
Other attractive candidate genes on Chr 2 are the two struc- 
tural genes encoding the 67- and 65-kD isoforms of glutamic 
acid decarboxylase (Gadl, Gad2).  These gene products are 
currently candidates for primary/5 cell autoantigens in NOD 
mice (14, 15). Although both Gad structural genes map to 
Chr 2 (16), they are positioned proximal to I11 in areas in 
which all markers typed to date have been NOD derived. 
Thus, NOD and NOR mice must be presumed to share the 
same Gad genes. 
Other Potential Regions Conferring Weak Resistance in NOR. 
Presence of a weaker  (and  recessive or poorly penetrant) 
resistance gene on the more distal segment of Chr 4 was 
suggested by a marginally significant segregation distortion 
associated with the D4MitI1  and the naturiuretic peptide 
precursor A (Nppa, formerly Pnd) markers. The possibility 
of an additional  weak resistance gene in linkage with the 
D1Mit46marker on the more distal segment of NOR Chr 
1 was also suggested. The Iddg', Idd11  r, and Idd5' resistance 
alleles have been previously identified in these same chro- 
mosomal regions in outcross of  NOD with other inbred strains 
(2, 4, 17, 18). Potential pathogenic interactions between Idd13 
and Idd5 and/or Iddg, were assessed  by comparing the geno- 
typic frequencies of//1, DIMit46,  and Nppa  in the 40% 
(35/87)  of nondiabetic F2 segregants that dearly expressed 
widespread destructive insulitis (insulitis grade 3-4 present 
in most islets) vs. the 20% (17/87)  exhibiting the lack of 
invasive insulitis (insulitis grades 0-1 in most islets). No such 
genetic interactions were discerned. Another relatively weak 
diabetes resistance allele (Idd4'), cosegregating with the ace- 
tylcholine receptor 13 subunit (Acrb) linkage marker on Chr 
11,  has  also been identified  in  outcross  of NOD  to  the 
C57BL/10  strain (2, 19). As shown in Fig. 1, NOR is dis- 
tinguished from NOD by polymorphisms in the Acrb gene, 
as well as in Nos2, the recently mapped gene for cytokine- 
inducible nitric oxide (20). However, neither Acrb nor any 
of the other markers in two more proximal  recombinant 
regions on Chr 11 cosegregated with IDDM in the F2 fe- 
males (Table 1). It is interesting to note that NOR has ac- 
quired a BKs-derived murine mammary tumor virus (Mtv9) 
proviral gene on Chr 12. Since Mtv gene products modify 
the T  cell repertoire,  this new locus in NOR would be a 
logical candidate  for the reduced  insulitis  and suppressed 
IDDM in NOR. However, no significant allelic distortion 
at either Mtv9 or DI2Mit51 was observed  in diabetic segregants. 
Congenic Transfer of Diabetes Resistance Alleles on Chr 2 of 
NOR to the NOD Genetic Background.  The strength of the 
NOR Idd13 resistance allele on Chr 2 in the absence of other, 
more weakly penetrant resistance modifiers (putatively Idd5" 
and Idd9' or IddI19 was assessed  by congenic transfer of the 
//1 and adenosine  deaminase  (Ada) linkage markers from NOR 
Chr 2 to the NOD background. At the N7 generation of 
backcrossing to NOD/Lt, segregants heterozygons for both 
the III and Ada linkage markers on Chr 2 were intercrossed. 
Mice homozygous for the NOR/Lt-derived Ill  allele were 
then selected from the resulting NvFt progeny and assessed 
for diabetes development through 1 yr of age. Controls con- 
sisted of NvFt progeny presumed homozygous or heterozy- 
gous for the NOD Idd13 susceptibility allele based upon I11 
genotyping. By this backcross  generation, mice were homozy- 
gous for NOD alleles at D1Mit46 and D4Mit11, respectively 
marking Idd5 and Iddg. As expected from the results of the 
F2 segregation analysis, 100% (12/12) of the Idd13  s/s segre- 
gants and 71% (24/34) of the Idd13  '/~ segregants became di- 
abetic by 1 yr of age. In contrast,  only 36%  (4/11) of the 
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period of time. Of these four diabetics homozygous for the 
NOR/11 allele, two were also homozygous for NOR markers 
at D2Mit47, D2Mit48, and Ada, whereas the other two were 
heterozygous for these markers. 
These results unequivocally establish the existence of Idd13  r 
on NOR Chr 2. However, in the absence of homozygosity 
for NOR resistance alleles at Idd5, Iddg, or Iddll, and per- 
haps more loci yet to be detected, homozygous expression 
of Idd13  r was incapable  of completely suppressing diabeto- 
genesis in NTF1 congenic females. Nevertheless, it should be 
noted that the first hyperglycemic Iddl3  `/' homozygote was 
not observed until 25 wk of age, when 41.2%  (14/34) of 
the Iddl3  s/' and 66.7% (8/12) of the IddI3 '/s segregants had 
developed IDDM (Fig.  2).  The decrease in overall IDDM 
incidence, coupled with the delayed time of onset in Iddl3 r/' 
congenic mice becoming hyperglycemic, support the conclu- 
sion that Idd13  ~  is a major, but not the sole determinant of 
diabetes resistance in NOR. The presence of additional resis- 
tance loci in NOR was further supported by analysis of a 
reciprocal congenic stock in which the NOD susceptibility 
markers  between  //1  and  Ada  were  transferred  onto  the 
NOR/Lt background in an effort to elicit IDDM. To date, 
after the same number of backcrosses (NT) to NOR, IDDM 
developed in only 1/5 females heterozygous for NOD linkage 
markers at 111 and Ada. However, this single female did not 
develop IDDM until 51 wk of age. 
Potential Relevance to IDDM Susceptibilit  7 in Humans.  The 
importance of various MHC alleles as primary determinants 
of IDDM susceptibility in humans (21-23)  is clearly estab- 
lished. However, it remains unresolved whether a fixed finite 
set of non-MHC susceptibility genes must interact with a 
susceptible  MHC haplotype to effect IDDM pathogenesis, 
or whether different combinations of polygenes can deleteri- 
ously interact  with  IDDM-predisposing MHC  alleles in 
different environments. Genetic analysis of IDDM suscepti- 
bility in NOD mice provides insight into this question. Cur- 
rently, the products of over 60 generations of brother-sister 
matings, NOD mice inherit the same gender-specific set of 
susceptibility genes through the germline. Thus, IDDM de- 
velopment in standard NOD mice is presumably catalyzed 
by interactions among a fixed set of (homozygous) polygenes. 
Other inbred strains of mice may be homozygous for different 
alleleic variants of genes capable of reducing or increasing 
IDDM susceptibility. When the NOD-specific diabetogenic 
interactions are disrupted by outcross to various inbred strains, 
and then reassorted into diabetogenic combinations in an F2 
or backcross generation, the full set of susceptibility modifiers 
defining the NOD genome may not need to be fully recon- 
stituted to elicit  IDDM.  Indeed, when H2g  7 haplotype is 
homozygous, the subsets  of non-MHC genes with which 
it must interact to effect pathogenesis may vary depending 
upon the genotype of the outcross partner strain.  This is il- 
lustrated by the fact that the C57BL/lOJ and NON/Lt in- 
bred strains apparently contribute not only Idd resistance al- 
leles, but also alleles capable of synergizing with NOD alleles 
to promote diabetogenesis  (2). 
The F2 cross-utilized in the present study identified a new 
locus on Chr 2 of NOR mice (Idd13) contributing strong 
IDDM resistance, but heretofore unrecognized in outcross 
with any other inbred progenitor. The existence oflddI3 has 
been verified by demonstration of low diabetes incidence in 
a congenic stock. Thus, when homozygous, the IddI3 resis- 
tance allele can block IDDM even in the presence  of the 
strongly diabetogenic H2e7 and a host of previously reported 
Idd susceptibility genes. Such non-MHC linked genes with 
the ability to modify diabetes susceptibility only when homo- 
zygous cannot be identified by backcross analysis. Ifa human 
homolog exists, it would either be on human Chr 2q13-21 
(marked by the ILl locus) or Chr 20pter-p12 (encompassing 
PCNA). These findings indicate that the nature of the specific 
genes contributing to IDDM susceptibility and the mode 
by which they do so vary according to the genomic compo- 
sition of the strain to which NOD is outcrossed. This study 
in mice provides understanding as to why it has been difficult 
to establish fixed patterns of inheritance of non-MHC genes 
contributing to IDDM susceptibility in humans either at the 
population level or within isolated  pedigrees. 
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Figure 2.  Diabetes resistance in a N7F1 stock of NOD mice congenic 
for  ~18  cM  of NOR/Lt  Chr  2  encompassing  Idd13,.  NOD  mice 
homozygous for the congenic segment presumed to encompass the resis- 
tance allele (Idd13,/,) were compared with segregants either homozygous 
(lddl3 s/')  or heterozygous (Idd13,/,)  for NOD genome in this region of 
Chr 2. 
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